International Journal of Hematology最新文献_第8页

A case of acute promyelocytic leukemia complicated by mitochondrial disease. 急性早幼粒细胞白血病合并线粒体疾病1例。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2025-08-01 Epub Date: 2025-05-01 DOI: 10.1007/s12185-025-03992-4

Yukari Sakurai, Masakatsu Yanagimachi, Mieko Ito, Ayana Hirose, Naoyuki Miyagawa, Dai Keino, Tomoko Yokosuka, Fuminori Iwasaki, Satoshi Hamanoue, Masae Shiomi, Shoko Goto, Tomohide Goto, Hiroaki Goto

引用次数: 0

Phase 2 multicenter study of pegaspargase in Japanese patients with previously untreated acute lymphoblastic leukemia. pegaspargase在日本急性淋巴细胞白血病患者中的2期多中心研究。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2025-08-01 Epub Date: 2025-03-31 DOI: 10.1007/s12185-025-03976-4

Katsuyoshi Koh, Yoshiyuki Kosaka, Yasuhiro Okamoto, Naoko Maeda, Atsushi Ogawa, Ryoji Kobayashi, Daisuke Hasegawa, Nobuhiro Koga, Adrien Tessier, Yelena Shvenke, Jian Zhu, Bouchra Benettaib, Keizo Horibe, Chitose Ogawa

{"title":"Phase 2 multicenter study of pegaspargase in Japanese patients with previously untreated acute lymphoblastic leukemia.","authors":"Katsuyoshi Koh, Yoshiyuki Kosaka, Yasuhiro Okamoto, Naoko Maeda, Atsushi Ogawa, Ryoji Kobayashi, Daisuke Hasegawa, Nobuhiro Koga, Adrien Tessier, Yelena Shvenke, Jian Zhu, Bouchra Benettaib, Keizo Horibe, Chitose Ogawa","doi":"10.1007/s12185-025-03976-4","DOIUrl":"10.1007/s12185-025-03976-4","url":null,"abstract":"Pegaspargase is a pegylated formulation of E. coli-derived asparaginase, which when combined with multi-agent chemotherapy is an effective, well-established therapy for acute lymphoblastic leukemia (ALL). This study evaluated the efficacy, safety and pharmacokinetics of lyophilized pegaspargase in the Japanese population. The study had two parts; the primary endpoint for Part 1 was the incidence and nature of treatment-emergent adverse events (TEAEs), including those related to pegaspargase, to determine the number of patients who experience intolerable toxicity during a tolerability assessment period. The primary endpoint for Part 2 was the percentage of patients with plasma asparaginase activity of ≥ 0.1 IU/ml 14 days after administration of the first dose of lyophilized pegaspargase. All 26 patients included in the safety analysis experienced at least one TEAE. Frequently reported TEAEs related to lyophilized pegaspargase included decreases in blood fibrinogen, antithrombin III, white blood cell count, and platelet count. No deaths were reported. Plasma asparaginase activity reached ≥ 0.1 IU/ml 5 min after the first dose of lyophilized pegaspargase and was maintained for 14 days in all patients with evaluable samples. The results of this study show that lyophilized pegaspargase represents an effective and well-tolerated first-line treatment option in Japanese patients with ALL.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"284-294"},"PeriodicalIF":1.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12304028/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment pathways and clinical outcomes in newly diagnosed multiple myeloma outside Europe and North America: The INTEGRATE study. 欧洲和北美以外地区新诊断多发性骨髓瘤的治疗途径和临床结果：INTEGRATE研究

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2025-08-01 Epub Date: 2025-04-15 DOI: 10.1007/s12185-025-03972-8

Kihyun Kim, Estelle Verburgh, Tatiana Mitina, Wenming Chen, Su-Peng Yeh, Natalia Schutz, Fahad Alsharif, Wee Joo Chng, Zhongwen Huang, Meral Beksac

{"title":"Treatment pathways and clinical outcomes in newly diagnosed multiple myeloma outside Europe and North America: The INTEGRATE study.","authors":"Kihyun Kim, Estelle Verburgh, Tatiana Mitina, Wenming Chen, Su-Peng Yeh, Natalia Schutz, Fahad Alsharif, Wee Joo Chng, Zhongwen Huang, Meral Beksac","doi":"10.1007/s12185-025-03972-8","DOIUrl":"10.1007/s12185-025-03972-8","url":null,"abstract":"Background: Real-world data on multiple myeloma (MM) outside Europe and North America are limited. The INTEGRATE study retrospectively assessed real-world treatment pathways and outcomes in MM from Argentina, China, South Korea, South Africa, Russia, Saudi Arabia, Taiwan, and Türkiye.Methods: Medical records (2010-2011) of patients (≥ 18 years) with newly diagnosed MM were analyzed. The primary endpoint was time to next treatment (TTNT). Secondary endpoints included treatment pathways and clinical outcomes stratified by stem cell transplantation (SCT).Results: Of 1511 patients analyzed (median age: 59.5 years), 32% had IgG kappa MM and 35.9% had International Staging System stage III disease. Bortezomib- and thalidomide-based chemotherapy regimens were the most common first- and second-line treatments; lenalidomide-based regimens were common in later lines. Median TTNT from initiation of first-line treatment was 39.5 months. Only 31.7% of patients received SCT at diagnosis, with improved outcomes versus those without SCT (median overall survival: 114.1 vs 85.9 months; 5-year relapse-free rates after first-line treatment: 58.2% vs 49.3%).Conclusion: Treatment strategies for MM outside Europe and North America align with guideline recommendations. More effective treatments and SCT at treatment initiation are needed. This study can guide future research in these regions utilizing newer treatment options.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"231-246"},"PeriodicalIF":1.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12304004/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144018755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Early cardiotoxicity in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis after HLA-haploidentical hematopoietic stem cell transplantation. hla -单倍体造血干细胞移植后以环磷酰胺为基础的移植物抗宿主病预防的早期心脏毒性

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2025-08-01 Epub Date: 2025-03-23 DOI: 10.1007/s12185-025-03970-w

Toshihiro Matsukawa, Junichi Sugita, Daigo Hashimoto, Masayuki Aiba, Kohei Okada, Takanori Teshima

{"title":"Early cardiotoxicity in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis after HLA-haploidentical hematopoietic stem cell transplantation.","authors":"Toshihiro Matsukawa, Junichi Sugita, Daigo Hashimoto, Masayuki Aiba, Kohei Okada, Takanori Teshima","doi":"10.1007/s12185-025-03970-w","DOIUrl":"10.1007/s12185-025-03970-w","url":null,"abstract":"Introduction: Post-transplant cyclophosphamide (PTCy)-based prophylaxis for graft-versus-host disease (GVHD) is widely used in HLA-haploidentical hematopoietic cell transplantation (haplo-HCT). One of the major drawbacks of PTCy is the risk of rare but potentially lethal cardiotoxicity, which prompted the development of regimens with reduced doses of PTCy.Methods: We retrospectively compared the incidence of early cardiotoxicity with standard-dose of PTCy (cyclophosphamide 50 mg/kg/day for 2 days, PTCy100) versus reduced-dose (40 mg/kg/day for 2 days, PTCy80). In total, 179 patients underwent PTCy-based haplo-HCT, including PTCy100 (n = 111) and PTCy80 (n = 68).Results: The PTCy80 group included significantly more elderly patients, patients who received reduced-intensity conditioning, and patients with a history of HCT than the PTCy100 group. Nine eligible patients (5.0%) experienced severe cardiotoxicity. The incidence of severe cardiotoxicity did not differ significant between PTCy80 and PTCy100 (4.4% vs. 5.4%; p = 1). The incidence of fatal cardiotoxicity was lower with PTCy80, but the small size may have prevented the difference from reaching statistical significance.Conclusion: Reducing the cyclophosphamide dose in PTCy-based GVHD prophylaxis may lower the risk of fatal cardiotoxicity without significantly altering the overall incidence of severe cardiotoxicity.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"247-256"},"PeriodicalIF":1.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143692048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dynamics of EBV-DNA load across sample types in pediatric EBV-HLH. EBV-DNA在儿童EBV-HLH中不同样本类型的负载动态。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2025-08-01 Epub Date: 2025-06-21 DOI: 10.1007/s12185-025-04026-9

Yu Furui, Kenichi Sakamoto, Eri Okura, Koichi Hirabayashi, Shoji Saito, Ryu Yanagisawa, Yozo Nakazawa

引用次数: 0

MYC-rearranged blastic plasmacytoid dendritic cell neoplasm with immunoblastoid features. 具有免疫母细胞样特征的myc重排母细胞浆细胞样树突状细胞瘤。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2025-08-01 Epub Date: 2025-06-28 DOI: 10.1007/s12185-025-04031-y

Radu Chiriac

引用次数: 0

Correction: Treatment pathways and clinical outcomes in newly diagnosed multiple myeloma outside Europe and North America: The INTEGRATE study. 更正：欧洲和北美以外新诊断多发性骨髓瘤的治疗途径和临床结果：INTEGRATE研究。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2025-08-01 DOI: 10.1007/s12185-025-04012-1

Kihyun Kim, Estelle Verburgh, Tatiana Mitina, Wenming Chen, Su-Peng Yeh, Natalia Schutz, Fahad Alsharif, Wee Joo Chng, Zhongwen Huang, Meral Beksac

引用次数: 0

Early withdrawal immunosuppression improved mixed chimerism in stem cell transplantation for pediatric aplastic anemia. 早期停药免疫抑制改善小儿再生障碍性贫血干细胞移植混合嵌合。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2025-08-01 Epub Date: 2025-05-23 DOI: 10.1007/s12185-025-03971-9

Xinan Wang, Xia Qin, Chengjuan Luo, Changying Luo, Jianmin Wang, Xiaohang Huang, Qiang Mi, Yuchen Lin, Jing Chen

{"title":"Early withdrawal immunosuppression improved mixed chimerism in stem cell transplantation for pediatric aplastic anemia.","authors":"Xinan Wang, Xia Qin, Chengjuan Luo, Changying Luo, Jianmin Wang, Xiaohang Huang, Qiang Mi, Yuchen Lin, Jing Chen","doi":"10.1007/s12185-025-03971-9","DOIUrl":"10.1007/s12185-025-03971-9","url":null,"abstract":"Mixed chimerism occurs frequently with the risk of graft rejection for aplastic anemia patients undergoing matched sibling donor hematopoietic stem cell transplantation in cyclophosphamide (CY) and anti-thymocyte globulin (ATG) conditioning. So far, no one knows how to adjust immunosuppression (IS) during MC. We retrospectively analyzed 87 consecutive pediatric patients. Early withdrawal (EW) IS and donor lymphocyte infusion were attempted to reverse MC. The rate of MC was 26% (n = 23). Low dose CY (120-150 mg/kg) was a risk factor for MC (P = 0.0002) and increasing the dosage of fludarabine did not eliminate it. Patients receiving 200 mg/kg CY had the lowest MC rate (8%) and best 3-year graft-versus-host disease/failure-free survival (GFFS; 95%). Donor chimerism in T cells was more sensitive than that in whole blood (P = 0.001). In 17 patients with early-onset MC, EW IS strategy was helpful in improving complete chimerism (CC) (EW cohort: 63 versus non-EW cohort: 295 days; P = 0.008). Our study shows that CY + ATG conditioning needs to be intensified to maintain engraftment and 200 mg/kg CY + 150 mg/m2 FLU is recommended for basic conditioning. The EW IS strategy should be considered as an important option to improve donor chimerism in early-onset MC. Clinical trial registration: URL: https://www.chictr.org.cn ; ChiCTR-1900023509. (Retrospective registration in 2019/5/31).","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"267-276"},"PeriodicalIF":1.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144127419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Allogeneic hematopoietic cell transplantation for autoinflammatory disorders. 同种异体造血细胞移植治疗自身炎性疾病。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2025-08-01 Epub Date: 2025-06-11 DOI: 10.1007/s12185-025-04021-0

Hirokazu Kanegane, Satoshi Miyamoto, Takahiro Kamiya, Hidenori Ohnishi, Ryuta Nishikomori, Andrew R Gennery, Takehiko Mori

引用次数: 0

Oral beclomethasone dipropionate therapy and prognostic plasma biomarkers for gastrointestinal graft-versus-host disease. 口服二丙酸倍氯米松治疗和胃肠道移植物抗宿主病的预后血浆生物标志物

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2025-08-01 Epub Date: 2025-03-25 DOI: 10.1007/s12185-025-03973-7

Yoshihiro Inamoto, Ayumu Ito, Toshihisa Nakashima, Asako Usui, Wataru Takeda, Takashi Tanaka, Sung-Won Kim, Shigehisa Kitano, Keisuke Watanabe, Kana Kusaba, Yu Aruga, Chiaki Ikeda, Minoru Kojima, Naoki Maezawa, Hirotaka Matsui, Hironobu Hashimoto, Chitose Ogawa, Takahiro Fukuda

{"title":"Oral beclomethasone dipropionate therapy and prognostic plasma biomarkers for gastrointestinal graft-versus-host disease.","authors":"Yoshihiro Inamoto, Ayumu Ito, Toshihisa Nakashima, Asako Usui, Wataru Takeda, Takashi Tanaka, Sung-Won Kim, Shigehisa Kitano, Keisuke Watanabe, Kana Kusaba, Yu Aruga, Chiaki Ikeda, Minoru Kojima, Naoki Maezawa, Hirotaka Matsui, Hironobu Hashimoto, Chitose Ogawa, Takahiro Fukuda","doi":"10.1007/s12185-025-03973-7","DOIUrl":"10.1007/s12185-025-03973-7","url":null,"abstract":"The real-world outcomes of oral beclomethasone dipropionate (BDP) for gastrointestinal graft-versus-host disease (GVHD) were evaluated in a single-center, prospective, observational study of 167 patients who developed histologically confirmed gastrointestinal GVHD. The median patient age was 55 years (range 10-71). The initial GVHD grade was mostly IIa (n = 138). BDP was used without systemic corticosteroids in 73 patients (44%), resulting in a decreased proportion of patients who received systemic corticosteroid administration from 76 to 58% (P = 0.001). The 4-week gastrointestinal response rate after BDP therapy, the primary endpoint, was 73% (95% CI 66-80%) compared with 68% (95% CI 55-78%) before BDP implementation. The proportion of patients with maximum gastrointestinal stage ≥ 2 was lower after than before BDP implementation (18% versus 35%, respectively, P = 0.004). The 1 year cumulative incidence of nonrelapse mortality (NRM) after gastrointestinal GVHD therapy was 15% after and 22% before BDP implementation (P = 0.12). The 4-week gastrointestinal response rate was lower in patients with elevated ST2 or REG3α levels than the remaining patients (36% versus 73%, P = 0.03). The 1 year NRM was higher in patients with elevated ST2 or ANG2 levels than the remaining patients (64% versus 12%, P < 0.001). This study characterized the outcomes of BDP therapy in real-world patients.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"257-266"},"PeriodicalIF":1.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0